SMi Group's 4th annual Cancer Vaccines 2015 conference is back this September

1. REASONS TO ATTEND IN 2015:
• Address the provocative issue of tumour genetic heterogeneity in
immunotherapy
• Understand the angiogenic process in both normal and tumour
and development
• Gain key industry perspective in combination therapies to advance
immune-oncology vaccines and enhance patient outcomes
• Envision RNA - vaccinology for building the next-generation of RNA
immunogens
• Look forward to our lead sponsored session:
Northwest Biotherapeutics's personalised DCVax® platform
technology that actively mobilizes the immune system against solid
tumour targets!
SMi Presents the 4th Annual Conference on...
16 - 17
SEPT
2015Marriott Regents Park Hotel, London, UK
Cancer Vaccines
PLUS TWO INTERACTIVE PRE-CONFERENCE WORKSHOPS
Tuesday 15th September 2015, Marriott Regents Park Hotel, London, UK
www.cancervaccinesevent.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
...Advancing Immuno-Oncology
@SMIPHARM
Workshop A
Stress is Good: Heat Shock Protein 70 as a Next-Generation
Theranostic with Broad Applicability in Oncology
Workshop Leaders: Alan Graham Pockley, 1Associate Director & Professor of Immunobiology, 2CEO,
3Founder and CEO 1Nottingham Trent University, 2Multimmune GmbH, 3Chromocyte Ltd, UK and
Dr. Gabriele Multhoff, 1University Professor in Experimentelle Radioonkologie und Strahlenbiologie,
2Group Leader, 1Technische Universität München, 1Helmholz Zentrum München
8.30am - 12.30pm
BOOK BY AUGUST 28TH TO SAVE £100
Workshop B
Tumour Genomic
Heterogeneity in Immunotherapeutics
Workshop Leaders: Michael G. Hanna, Jr. Founder &
Chairman Emeritus, Vaccinogen, Inc.
1.30pm - 5.30pm
Registered
A
ttendees
Include:
BoehringerIngelheim
Im
m
unicum
A
B
ShionogiLtd
Theravectys
CHAIR FOR 2015:
Professor Farzin Farzaneh, Professor of Molecular
Medicine, Kings College London
SPONSOR SPEAKER:
Linda F. Powers, Chair and Chief Executive Officer,
Northwest Biotherapeutics
FEATURED SPEAKERS INCLUDE:
• Michael G. Hanna, Jr. Founder & Chairman Emeritus,
Vaccinogen, Inc.
• Sebastian Kreiter, VP Immunotherapy, BioNTech RNA
Pharmaceuticals
• Vaios Karanikas, Biomarker Experimental Medicine Leader,
Tumour Immunology, Roche Innovation Centre Zurich
• Thomas Felzmann, CEO, Activartis Biotech GmbH
• Peter L. Andersen, VP Vaccine R&D, Statens Serum Institut
• Dr. Ravi Madan, National Cancer Institute
• Felipe Bedoya, Director Product Development Laboratory,
University of Pennsylvania
Sponsor: Northwest Biotherapeutics

2. Register online at: www.cancervaccinesevent.com • Alternatively
Cancer Vaccines
Day One | Wednesday 16th September 2015
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Farzin Farzaneh, Professor of Molecular Medicine, Kings
College London
NEW FRONTIERS IN VACCINE DEVELOPMENT
OPENING ADDRESS:
9.10 The Provocative Issue of Tumor Genetic Heterogeneity in
Immunotherapy
•You cannot treat a Heterogeneous disease with a
Homogeneous treatment
•Immunotherapy should be aimed at preventing recurrence
not treating established tumors
•Immune longevity in Autologous Vaccine Immunotherapy
Michael G. Hanna, Jr. Founder & Chairman Emeritus,
Vaccinogen, Inc.
9.50 Translational Biomarkers and Diagnostic Tools in Oncology
•Analysis and interpretation to support key decisions during
the early clinical development
•Enabling strategies and their implementation for early
preclinical/clinical studies
•Validating the predictive utility of biomarker candidates
Vaios Karanikas, Biomarker Experimental Medicine Leader,
Tumour Immunology, Roche Innovation Centre Zurich
10.30 Morning Coffee
11.00 Establishing a fully-personalised cancer treatment
•Phase I/II clinical trials
•Augmenting T Cell response to
•Vaccine and checkpoint blockade combinations
Dr.Ravi Madan, National Cancer Institute
SUSTAINABLE CARE AND ANTI-TUMOUR RESPONSE
11.40 EFour into One does go: The use of integrated genomic,
proteomic, immunological and bioinformatic platforms to
identify novel immunological biomarkers of disease and
predict outcomes of disease
•Tumour-mediated immunoregulation and immunological
barriers to successful therapeutic outcomes
•Immunomics: Integrating platforms for the discovery of new
cancer biomarkers
•Case Study: Immunomics in prostate and breast cancer
Alan Graham Pockley, Associate Director & Professor of
Immunobiology, Nottingham Trent University
12.20 Networking Lunch
1.30 DCVax®: Novel Personalized Immune Therapies for
Solid Tumors
•Ms. Powers will discuss NW Bio’s DCVax® platform
technology, a personalized, dendritic cell based active
immunotherapy for solid tumors.
•Unlike conventional cancer drugs and other immune
therapies, which use one active agent to hit one target on
the cancer, DCVax mobilizes many active agents of the
immune system to hit many targets on the cancer.
Linda F. Powers, Chair and Chief Executive Officer, Northwest
Biotherapeutics
2.10 Combination therapies to advance
immune-oncology vaccines and enhance
patient outcomes
•Multi-modal cancer immunotherapy
- combining vaccines & ICP inhibitors
•Prognostic and Predictive Markers to Support
Identification of Effective Immunotherapy Combinations
•Case study
Thomas Felzmann, CEO, Activartis Biotech GmbH
2.50 Afternoon Tea
3.20 Understanding Tumor-Host Interactions
•How to individualize cancer treatment
Professor Dr. Dirk Jager, Director of Medical Oncology,
National Center for Tumor Diseases, University Medical Center
4.00 Oncolytic virotherapy: Cancer immunotherapy as nature
intended
Hardev Pandha, Professor & Consultant Physician of Medical
Oncology, Director, Surrey Cancer Research Institute,
University of Surrey
4.40 PANEL DISCUSSION:
Where is the future for Cancer Vaccines?
•When should we use personalised and
non-personalised care?
•How can we develop further understanding
in identifying novel pathways?
•How accessible would fully - personalised treatments
become?
•How will technology and data systems need to change
in order to allow personalised treatment to evolve?
Panel leader: Farzin Farzenah, Professor of Molecular
Medicine, Kings College London
Panellists:
Dr. Ravi Madan, National Cancer Institute
Linda F. Powers, Chair and Chief Executive Officer, Northwest
Biotherapeutics
5.20 Chairman's Closing Remarks and Close of Day One
5.30 Drinks reception - (5.30 - 7.00)
Sponsored by Northwest Biotherapeutics
Industry
Perspective
Official media partners
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your
company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client
base within the context of an independent discussion specific to your industry. Should you wish to join the increasing
number of companies benefiting from sponsoring our conferences please call: Alia Malick on
+44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
Northwest Bio is developing DCVax dendritic cell-based immunotherapeutic cancer
vaccinesdesignedtotreatabroadrangeofsolidtumorcancersmoreeffectivelythan
current treatments, and without the side effects of chemotherapy. The Company’s
lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma
multiforme (GBM), the most aggressive and lethal brain cancer. The Company’s second product, DCVax-Direct,
is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers.
Sponsored by

3. Want to know how you can get involved? Interested in promoting your services to this market?
Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162, or email: tarri@smi-online.co.uk
fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Cancer Vaccines
Day Two | Thursday 17th September 2015
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Farzin Farzaneh, Professor of Molecular Medicine, Kings
College London
IMPROVEMENTS IN TARGETED RESPONSE
OPENING ADDRESS:
9.10 Therapeutic Cancer Vaccines
•Tumour immunology and interactions between cancer and
the immune system
•Immune based sculpting of the tumour - selection of the
most resistant cancer cells
•Cancer mediated immune suppression - inhibition of
surveillance and stimulation of immune check points
•New therapeutic interventions: Active vaccination
strategies, check point inhibition and targeted cytotolytic
cells (CARs and TCR modified T cells)
Farzin Farzenah, Professor of Molecular Medicine, Kings
College London
9.50 RNA - vaccinology: From ware-houses to actively
personalized cancer vaccines
•Simulating tumour-specific antigen recognition
•Epitope Design Enables a Pipeline of Multi-Antigen DNA
Tumor Vaccines
•Neo-antigen–specific CD4+ T cells recognize mutated
neo-antigens
Sebastian Kreiter, VP Immunotherapy, BioNTech RNA
Pharmaceuticals
10.30 Morning Coffee
11.00 Developments and clinical trials in allogeneic cell-based
vaccines
•Deriving allogeneic dendritic cells for future scalability
and feasibility of cellular cancer vaccines
•Practicalities of vaccine clinical trials
•Cancer vaccine trial designs
•Implementing targeting of known tumour antigens
John Maudsley, CEO, Cancer Vaccines Ltd.
11.40 Case study: Dendritic cell vaccine development for
colorectal cancer.
Eric Liere, CEO, DanDrit Biotech
12.20 Networking Lunch
1.30 Differentiation pathways of effector and memory CD8+ T cells
•The protective role of memory CD8+ T cell subsets
•Signaling pathways that regulate effector and memory
CD8+ T cell generation
•Memory T cell subsets generated by vaccines and natural
infection
Aymen Al-Shamkhani, Professor of Immunology, University of
Southampton
2.10 Long-term maintenance of T cell memory by liposomes
•Mode of action for cationic liposomes and the CAF
adjuvants
•The role of central memory cells in the control of a chronic
infection - Experience from Tuberculosis
•Data from clinical trials
Peter L. Andersen, VP Vaccine R&D, Statens Serum Institut
2.50 Round Table Discussion: Engineering materials
to improve immune response
•What are some of the biggest challenges that
limit immune response in DNA Vaccinations?
•Development of combination treatments
- which ones are best?
•Translating antigen expression - or lack of it
3.30 Peptides or DNA vaccines? Could Immunobody® be the
answer?
•Long peptides vaccination require adjuvants but different
peptide work best with different adjuvant
•DNA vaccine do not always generate high avidity T-cells
•Could Immunobody® be the Universal antigen delivery
system?
Stephanie McArdle, Senior Research Scientist, Nottingham
Trent University
4.10 Gene Editing for Immunotherapy
•Virus - vector to infiltrate the tumour
•Discovery of Novel Targets for Genetic Engineering of
Tumor-Specific T Cells
•Mutation-targeting RNA-based vaccines
Felipe Bedoya, Director Product Development Laboratory,
University of Pennsylvania
4.50 Afternoon Tea
5.20 PANEL DISCUSSION:
•Are we closer to achieving sustained
antitumor immune response?
•Driving next generation tools in cancer
immunotherapy
•What progresses in the Genome-wide mutation
identification initiatives have helped personalised
immunology?
Panel leader: Farzin Farzenah, Professor of Molecular
Medicine, Kings College London
Panellists:
Sebastian Kreiter, VP Immunotherapy, BioNTech RNA
Pharmaceuticals
Peter L. Andersen, VP Vaccine R&D, Statens Serum Institut
6.00 Chairman’s Closing Remarks and Close of Day Two
Supported by

4. Overview of workshop;
Did you know that, in addition to being an intracellular
molecule, heat shock protein 70 (Hsp70) can be released
from cancer cells, and that it is selectively expressed on the
plasma membranes of wide range of tumour entities (~60 to
80%)? Did you also know that chemo (radio) therapy can
enhance the expression of this unique membrane form of
Hsp70? This workshop will provide a comprehensive insight
into the approaches for tumour targeting and imaging that
have been developed using this platform, and the
theranostic potential of Hsp70 in oncology.
Key Benefits of Attending:
This workshop is a unique opportunity to discuss the
therapeutic, targeting and imaging platforms that have
been developed around this concept and how the
technology might be able to enhance and improve current
therapeutic approaches in a range of cancer settings. It will
therefore be of great interest and relevance to all those
working in pre-clinical and clinical diagnostic and
therapeutic translational oncology.
Programme
8.30 Registration and Coffee
9.00 Circulating Hsp70 as a biomarker of disease in
cancer
Discussion - A. Graham Pockley
9.30 Membrane Hsp70 expression in cancer and its
theranostic potential
Discussion - Gabriele Multhoff
10.30 Coffee Break
11.00 Imaging and targeting of membrane Hsp70
expressing tumours using a novel tumour-
penetrating peptide (TPP) Discussion - Stefan Stangl
12.30 Conclusions & Close
A. Graham Pockley & Gabriele Multhoff
About the workshop host:
Graham Pockley is Professor of Immunobiology and the
Associate Director of the John van Geest Cancer Research
Centre (JvGCRC) at Nottingham Trent University. He is also
the CEO of multimmune GmbH, Munich. He has an
international reputation in heat shock (stress) proteins and
the development and validation of new immunological
assays and platforms in the fields of flow cytometry, immune
monitoring, and cell analysis.
About the organisation:
The JvGCRC (www.ntu.ac.uk/vangeest)
at Nottingham Trent University uses its
integrated genomic, proteomic,
immunological and bioinformatics
platforms to identify biomarkers of disease and disease
progression, predict therapeutic responses and the develop
diagnostic and immunotherapeutic approaches.
Multimmune GmbH’s unique and proprietary technology
platform is based on the discovery that a cell surface bound
form of Hp70 is selectively expressed on many tumour types
by Gabriele Multhoff and Claus Botzler. multimmune is
focused on the development of innovative therapeutic
approaches for treating
cancers that express this
cell surface-expressed
form of Hsp70.
HALF DAY PRE- CONFERENCE WORKSHOP A
Tuesday 15th September 2015
8.30am – 12.30pm
Marriott Regents Park Hotel, London, UK
Stress is Good: Heat Shock Protein 70 as
a Next-Generation Theranostic with
Broad Applicability in Oncology
Workshop Leaders:
Alan Graham Pockley, 2
Associate Director &
Professor of Immunobiology, 2
CEO, 3
Founder
and CEO 1
Nottingham Trent University,
2
Multimmune GmbH, 3
Chromocyte Ltd, UK
Prof. Gabriele Multhoff,
1
University Professor in Experimentelle
Radioonkologie und Strahlenbiologie, and
2
Group Leader of Clinical Cooperation Group
in Tumor Biology, 1
Technische Universität
München, 2
Helmholz Zentrum München

5. Overview of workshop:
Science highlighted cancer immunotherapy as the “2013
Breakthrough of the Year”. More to the point, they stated
"this year marks a turning point in cancer, as long-sought
efforts to unleash the immune system against tumors are
paying off - even if the future remains a question mark."
Most of the celebration involves the compelling results of
targeted agents designed to reactivate the immune
system by manipulating the PD-1/PD-L1 and CTLA-4
pathways. Active specific immunotherapy (ASI) with
cancer vaccines has the potential to be that
transformative technology by embracing the recently
demonstrated genomic heterogeneity of tumor cells
which represent the entire antigenic diversity of each
patient’s primary tumor.
Key learning benefits from attending:
• The impact in Antigen discovery for Cancer Vaccines
• Patient population selection for treatment
• In vivo and in vitro monitoring of the treatment and
clinical endpoints
• Potential for development of epitope based vaccines
for treatment and prevention
Programme
1.30 Registration and Coffee
2.00 Antigen discovery for Cancer Vaccines
3.00 Afternoon Tea
3.30 Patient population selection for treatment
4.30 Potential for development of epitope based
vaccines for treatment and prevention
5.30 Close of workshop
About the workshop host:
Dr. Michael G. Hanna, Jr. received his PhD in experimental
pathology and immunology from the University of
Tennessee in 1964. He was on staff of the Oak Ridge
National Laboratory, biology division from 1964-75. During
this period he pioneered the early concepts of tumor
immunology. He also served as a consultant with NASA for
the lunar receiving laboratory during Apollo 11 and 12, for
which his expertise in immunology was used in the testing
of the lunar core powder for immunogenic or pathogenic
materials. Dr. Hanna served during1975–83 as Director of
the National Cancer Institute, Frederick Cancer Research
Center (MD, USA). In this position he created a center of
research excellence for the NCI and established the
Biological Response Modifier Program which led in the
development of resources for immunotherapy of cancer.
About the organisation:
Vaccinogen, Inc. is a cancer vaccine company that is
clinically testing its OncoVAX® treatment which is
designed to prevent the recurrence of colon cancer and
potentially other solid tumors. It is a patented process that
circumvents the extreme diversity of tumor cells by
leveraging a patient’s own live tumor cells to launch a
broad immune response against colon cancer. The
Company believes that OncoVAX, at an optimum dose
and regimen, is the first colon cancer vaccine to
demonstrate effectiveness in both preventing cancer
recurrence after surgical resection of the primary tumor
and addressing the diversity of cancer cells. OncoVAX
has completed five clinical studies, including a Phase III
trial with the optimum dose and regimen. The Company
expects to begin a pivotal Phase IIIb trial under an FDA
Special Protocol Assessment (SPA) classification in the
second quarter of 2015. The Company’s shares trade on
the OTC.QB under the symbol “VGEN”. More information
is available at ww.vaccinogeninc.com
HALF DAY PRE- CONFERENCE WORKSHOP B
Tuesday 15th September 2015
1.30pm – 5.30pm
Marriott Regents Park Hotel, London, UK
Tumour Genomic Heterogeneity
in Immunotherapies
Workshop Leader:
Michael G. Hanna,
Jr. Founder & Chairman Emeritus,
Vaccinogen, Inc.

6. FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
CANCER VACCINES
Conference: Wednesday 16th & Thursday 17th September 2015, Marriott Regents Park Hotel, London, UK
Workshops: Tuesday 15th September 2015, London, UK
4 WAYS TO REGISTER
www.cancervaccinesevent.com
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be
paid immediately and prior to the start of the event. If payment has not been received then credit
card details will be requested and payment taken before entry to the event. Bookings within 7 days
ofeventrequirepaymentonbooking.AccesstotheDocumentPortalwillnotbegivenuntilpayment
has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we have
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
products and services. Unless you tick here □we may also share your data with third parties offering
complementary products or services. If you have any queries or want to update any of the data that
we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit
our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the
attached letter.
Unique Reference Number
Our Reference LVP-150
Terms and Conditions of Booking
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
VENUE Marriott Regents Park Hotel, 128 King Henry's Road, London, NW3 3ST
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
□ Book by 29th May 2015 to receive £300 off the conference price
□ Book by 30th June 2015 to receive £200 off the conference price
□ Book by 28th August 2015 to receive £100 off the conference price
EARLY BIRD
DISCOUNT
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-150 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATION
I cannot attend but would like to purchase access to the following Document
Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on
Document portal and literature distribution for all UK customers and for those EU Customers
not supplying a registration number for their own country here.
______________________________________________________________________________________________
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & 2 Workshops £2697.00 + VAT £3236.40
□ Conference & 1 Workshop AM □ PM □ £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ 1 Workshop only AM □ PM □ £599.00 + VAT £718.80
□ 2 Workshops £1198.00 + VAT £1437.60
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to the
Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.